BBHC
MDGL icon

Brown Brothers Harriman & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brown Brothers Harriman & Co’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69K Hold
5
– – ﹤0.01% 1687
2026
Q1 		$2.62K Hold
5
– – ﹤0.01% 1658
2025
Q4 		$2.91K Hold
5
– – ﹤0.01% 1647
2025
Q3 		$2.29K Hold
5
– – ﹤0.01% 1552
2025
Q2 		$1.51K Buy
+5
New +$1.49K ﹤0.01% 1461

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Brothers Harriman & Co's MDGL Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 5 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

Brown Brothers Harriman & Co first reported a position in MDGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.91K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Brown Brothers Harriman & Co held 5 shares of Madrigal Pharmaceuticals worth $2.69K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1687 holding.
  • Brown Brothers Harriman & Co first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Brown Brothers Harriman & Co's Madrigal Pharmaceuticals position peaked at $2.91K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.